Teradyne Inc. diskutieren
Teradyne, Inc. (NASDAQ: TER) had its price target raised by analysts at Susquehanna from $145.00 to $165.00. They now have a "positive" rating on the stock.
Ratings data for TER provided by MarketBeat
Teradyne, Inc. (NASDAQ: TER) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $160.00 price target on the stock.
Ratings data for TER provided by MarketBeat
Teradyne, Inc. (NASDAQ: TER) had its price target lowered by analysts at Northland Securities from $154.00 to $140.00. They now have an "outperform" rating on the stock.
Ratings data for TER provided by MarketBeat
Teradyne, Inc. (NASDAQ: TER) had its price target lowered by analysts at KeyCorp from $180.00 to $150.00. They now have an "overweight" rating on the stock.
Ratings data for TER provided by MarketBeat
Teradyne, Inc. (NASDAQ: TER) had its price target lowered by analysts at JPMorgan Chase & Co. from $158.00 to $145.00. They now have an "overweight" rating on the stock.
Ratings data for TER provided by MarketBeat
Teradyne, Inc. (NASDAQ: TER) had its price target lowered by analysts at UBS Group AG from $160.00 to $155.00. They now have a "buy" rating on the stock.
Ratings data for TER provided by MarketBeat
Teradyne, Inc. (NASDAQ: TER) is now covered by analysts at Vertical Research. They set a "buy" rating and a $135.00 price target on the stock.
Ratings data for TER provided by MarketBeat
Teradyne, Inc. (NASDAQ: TER) had its price target lowered by analysts at JPMorgan Chase & Co. from $145.00 to $120.00. They now have an "overweight" rating on the stock.
Ratings data for TER provided by MarketBeat
Teradyne, Inc. (NASDAQ: TER) had its price target lowered by analysts at Bank of America Co. from $100.00 to $85.00. They now have an "underperform" rating on the stock.
Ratings data for TER provided by MarketBeat
Teradyne, Inc. (NASDAQ: TER) had its price target lowered by analysts at TD Cowen from $135.00 to $110.00. They now have a "buy" rating on the stock.
Ratings data for TER provided by MarketBeat
Teradyne, Inc. (NASDAQ: TER) had its price target lowered by analysts at KeyCorp from $150.00 to $140.00. They now have an "overweight" rating on the stock.
Ratings data for TER provided by MarketBeat
Teradyne, Inc. (NASDAQ: TER) had its price target lowered by analysts at Cantor Fitzgerald from $150.00 to $110.00. They now have an "overweight" rating on the stock.
Ratings data for TER provided by MarketBeat
Teradyne, Inc. (NASDAQ: TER) was given a new $130.00 price target on by analysts at UBS Group AG. They now have a "buy" rating on the stock.
Ratings data for TER provided by MarketBeat
Teradyne, Inc. (NASDAQ: TER) had its price target lowered by analysts at Susquehanna from $165.00 to $155.00. They now have a "positive" rating on the stock.
Ratings data for TER provided by MarketBeat
Teradyne, Inc. (NASDAQ: TER) had its price target lowered by analysts at Citigroup Inc. from $130.00 to $100.00. They now have a "buy" rating on the stock.
Ratings data for TER provided by MarketBeat
Teradyne, Inc. (NASDAQ: TER) had its price target lowered by analysts at Robert W. Baird from $140.00 to $110.00. They now have an "outperform" rating on the stock.
Ratings data for TER provided by MarketBeat
Teradyne, Inc. (NASDAQ: TER) had its price target lowered by analysts at Morgan Stanley from $112.00 to $81.00. They now have an "underweight" rating on the stock.
Ratings data for TER provided by MarketBeat
Teradyne, Inc. (NASDAQ: TER) had its price target lowered by analysts at Morgan Stanley from $81.00 to $69.00. They now have an "underweight" rating on the stock.
Ratings data for TER provided by MarketBeat
Teradyne, Inc. (NASDAQ: TER) had its price target lowered by analysts at JPMorgan Chase & Co. from $120.00 to $92.00. They now have an "overweight" rating on the stock.
Ratings data for TER provided by MarketBeat
Teradyne, Inc. (NASDAQ: TER) had its price target lowered by analysts at Susquehanna from $155.00 to $133.00. They now have a "positive" rating on the stock.
Ratings data for TER provided by MarketBeat
Neueste Beiträge
HC_Wainwright in Discuss Nektar Therapeutics